Edwards Lifesciences Corporation

3 days ago · zacks.com

Edwards Lifesciences Corp. EW is scheduled to report third-quarter 2026 results on Nov. 4, after the market closes.

3 days ago · zacks.com

Beyond analysts' top-and-bottom-line estimates for Edwards Lifesciences (EW), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.

4 days ago · seekingalpha.com

Edwards Lifesciences gets a buy for my initial rating. Strengths come from recent FDA approvals, a niche portfolio serving the cardiology segment, and impressive operating margins and operating cash flow. EW's price return vs. key benchmarks showed weakness this year.

11 days ago · zacks.com

Edwards Lifesciences' TMTT and TAVR growth, strong clinical evidence and solid balance sheet support expansion, but tariffs and currency headwinds threaten margins.

26 days ago · businesswire.com

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Lifescie.

28 days ago · businesswire.com

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team. A live webcast of the event will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived versio.

1 month ago · businesswire.com

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement. For many pediatric patients, pulmonary valve replacement is not a one-time event. The AUTUS valve is the first FDA-approved surgical pulmonary valve designed for pediatric anatomy,.

1 month ago · gurufocus.com

On September 30, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown a mixed price performance recently, with a ye

2 months ago · marketbeat.com

Edwards Lifesciences NYSE: EW outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE, SAPIEN M3 and surgical therapies.

2 months ago · seekingalpha.com

Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript